Quick Answer
LISATA THERAPEUTICS, INC. reported Operating Income Loss of -$18.21 million for the year ending 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +18.7% in Operating Income Loss from 2024 to 2025.
- This data is from LISATA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$3.50 million | Q3 2010: -$5.74 million | Q1 2011: -$7.08 million | Q2 2011: -$10.04 million | Q3 2011: -$7.23 million | Q1 2012: -$7.54 million | Q2 2012: -$6.81 million | Q3 2012: -$8.09 million | Q1 2013: -$8.83 million | Q2 2013: -$8.17 million | Q3 2013: -$9.31 million | Q1 2014: -$13.50 million | Q2 2014: -$12.43 million | Q3 2014: -$16.26 million | Q1 2015: -$18.09 million | Q2 2015: -$25.67 million | Q3 2015: -$10.38 million | Q1 2016: -$11.07 million | Q2 2016: -$7.41 million | Q3 2016: -$5.73 million | Q1 2017: -$6.43 million | Q2 2017: -$7.71 million | Q3 2017: -$6.13 million | Q1 2018: -$5.16 million | Q2 2018: -$4.27 million | Q3 2018: -$3.76 million | Q1 2019: -$4.59 million | Q2 2019: -$5.35 million | Q3 2019: -$5.07 million | Q1 2020: -$4.06 million | Q2 2020: -$4.29 million | Q3 2020: -$5.35 million | Q1 2021: -$8.09 million | Q2 2021: -$7.15 million | Q3 2021: -$6.97 million | Q1 2022: -$6.62 million | Q2 2022: -$6.72 million | Q3 2022: -$37.72 million | Q1 2023: -$6.84 million | Q2 2023: -$6.88 million | Q3 2023: -$5.96 million | Q1 2024: -$6.60 million | Q2 2024: -$5.52 million | Q3 2024: -$5.34 million | Q1 2025: -$5.85 million | Q2 2025: -$4.87 million | Q3 2025: -$4.41 million.
- Over the full 16 years of available data (2010 to 2025), LISATA THERAPEUTICS, INC.'s Operating Income Loss has grown by 3.5%.
- Historical annual values: Fiscal year 2025: -$18.21 million | Fiscal year 2024: -$22.41 million | Fiscal year 2023: -$25.71 million | Fiscal year 2022: -$57.60 million | Fiscal year 2021: -$29.05 million | Fiscal year 2020: -$19.15 million | Fiscal year 2019: -$20.09 million | Fiscal year 2018: -$16.99 million | Fiscal year 2017: -$27.59 million | Fiscal year 2016: -$29.50 million | Fiscal year 2015: -$113.85 million | Fiscal year 2014: -$57.74 million | Fiscal year 2013: -$36.81 million | Fiscal year 2012: -$30.39 million | Fiscal year 2011: -$34.00 million | Fiscal year 2010: -$18.88 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: